EU regulator backs Eli Lilly's Alzheimer's drug after initial rejection
US FDA approves gradual dosing for Lilly Alzheimer's drug
Update On Cost-Effectiveness Evaluation Of LEQEMBI By Japan's Health Ministry Council
Factbox: Trump's tariffs and threatened trade actions
Factbox: Trump's tariffs and threatened trade actions
Factbox: Trump's tariffs and threatened trade actions
Obtain Favorable Decision In Patent Infringement Litigation Related To Lenvatinib In The U.S.
US FDA clears first blood test for Alzheimer's detection (updated)
Brief: Eisai Projects Leqembi® Revenue To Total JPY 76.5 Billion For FY 2025
Table: Eisai -2024/25 parent results
Table: Eisai -2024/25 group results (IFRS)
Factbox: Trump's tariffs and threatened trade actions
Factbox: Trump's tariffs and threatened trade actions
Biogen's results beat estimates on strength in rare disease drugs (updated)
Biogen beats quarterly profit estimates on strong demand for rare disease drugs
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease (updated)
EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease
Brief: BioArctic AB Says EU Approves Leqembi (Lecanemab) For Treatment Of Early Alzheimer's Disease
Factbox: Trump's tariffs and threatened trade actions